GH Stock Price Today (October 2026) — Guardant Health, Inc. Analysis & Key Metrics 2026-10-20
Guardant Health, Inc. (GH) is trading at $162.59, up 2.98% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $201.64 (24.0% upside).
- Volatility is high (46.30% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (44.30% YoY) alongside competitive pressures in the Diagnostics & Research space.
GH Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Guardant Health, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $22.46B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+24.0% upside potential
Key Investor Questions About GH
What investors need to know before buying
Based on current market data, GH presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 43.74)
- Fundamentals say: Mixed signals (nuanced financial profile)
GH's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for GH investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $1.70B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, GH stock traded between $66.59 and $191.05 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 46.30% annualized volatility and β=0.91, the stock exhibits moderate correlation to market moves—making GH suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
Should You Be Worried About Tempus AI Stock?
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
Guardant Health (GH) After Shield And Reveal Data Is The Undervalued Story Still Intact
Is Guardant Health (GH) At A Turning Point After Its Patent Setback?
Latest TickZen Insights
All insights →No TickZen article on GH yet. Our newest analysis:
Explore More Analysis for GH
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 5, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Guardant Health, Inc.
Guardant Health, Inc. (GH) is currently trading at $162.59. The RSI (14-day) is at 43.7, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $201.64 implies 24.0% upside from current levels. Volatility is high at 46.3% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Guardant Health, Inc. (GH): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Sales is 19.04. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering GH, the consensus price target is $201.64. This represents a 24.0% upside from the current price of $162.59. The range spans from a low target of $105.00 to a high target of $240.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Guardant Health, Inc. (GH) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Guardant Health, Inc. (GH) investors include: 1. High volatility (46.3% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Guardant Health, Inc.'s (GH) current debt and financial health profile: Total debt stands at $1.70B. The current ratio is 4.03, indicating strong short-term liquidity. The quick ratio is 3.53. The company holds $1.05B in cash and equivalents. Free cash flow is positive at $26.61M, providing a cushion for debt servicing and shareholder returns.